Hand-Foot Syndrome (HFS) is commonly reported in treatment with liposomal doxorubicin (LD) and capecitabine. We present 3 cases of HFS recall with gefitinib after previous LD therapy. The first 2 cases, in patients with head and neck cancer previously treated with paclitaxel and LD, developed on subsequent therapy with gefitinib. One patient had previously developed HFS on LD and the other had not. In both patients HFS resolved after stopping gefitinib. The third case is of a patient with ovarian cancer, also treated with gefitinib after LD, who developed HFS recall which resolved after gefitinib withdrawal. HFS can occur with gefitinib in patients who have been previously exposed to agents known to cause HFS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07357900600814847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of Osborne's Ligament Suspension and Ulnar Nerve Anterior Transposition in Conjunction with Transcutaneous Electrical Nerve Stimulation for Managing Cubital Tunnel Syndrome: A Retrospective Study.
Ann Ital Chir
December 2024
Department of Hand & Foot and Reconstructive Microsurgery, The First Hospital of Qinhuangdao, 066000 Qinhuangdao, Hebei, China.
Aim: To explore the effectiveness and safety of Osborne's ligament suspension and ulnar nerve anterior transposition (OLSUNAT) in conjunction with transcutaneous electrical nerve stimulation (TENS) for managing cubital tunnel syndrome (CTS).
Methods: A total of 116 individuals diagnosed with CTS who underwent OLSUNAT in our hospital between October 2020 and December 2023 were retrospectively selected. They were divided into a treatment group (62 cases) and a control group (54 cases) based on whether they received subsequent TENS.
Probiotics prevent pegylated liposomal doxorubicin-associated hand-foot syndrome and oral mucositis of breast cancer patients following surgery and chemotherapy:a randomized placebo-controlled trial.
Int J Surg
December 2024
Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Background: Hand-foot syndrome (HFS) and oral mucositis (OM) are common adverse events during cancer chemotherapy and can significantly decrease patients' quality of life and chemotherapy adaptation, however, prevention strategies of these complications yet to be established.
Methods: Patients with stage I-III breast cancer, who had surgery and needed pegylated liposomal doxorubicin (PLD)-based adjuvant chemotherapy were screened, recruited and randomly assigned to receive either probiotics or placebo (three capsules, twice/day) treatment during the course of chemotherapy from Nov. 2019 to Aug.
Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.
Cancer Cell Int
December 2024
Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China.
Background: The objective of this study was to compare the efficacy and safety of subsequent chemotherapy with single eribulin or utidelone combined with a capecitabine regimen in patients with advanced breast cancer who had previously been treated with anthracyclines and paclitaxel.
Methods: This work was a retrospective analysis of 85 patients from July 2018 to July 2023. Forty-two and 43 patients were treated with the eribulin regimen and the utidelone/capecitabine regimen, respectively.
Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon L858M/L861R mutations.
Front Pharmacol
November 2024
Department of R&D, Hangzhou Repugene Technology Co., Ltd., Hangzhou, China.
Targeted therapy has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients carrying common mutations, but the standard care for patients with rare mutations has not been well established. Here, we report a 65-year-old female diagnosed with stage IIIC lung adenocarcinoma located in the right inferior lobe, harboring uncommon L858M/L861R mutations. Remarkably, 24 days post-treatment of afatinib and anlotinib, chest CT scans demonstrated significant shrinkage of primary lesion, indicating a partial response.
View Article and Find Full Text PDFA Multidisciplinary Approach to Hypermobility Spectrum Disorder, Raynaud's Phenomenon, and Biomechanical Soft Tissue Injuries in an Adolescent Boy: A Case Report.
Clin Case Rep
December 2024
Division of Movement Science and Exercise Therapy, Department of Sport Science, Faculty of Medicine and Health Sciences Stellenbosch University Stellenbosch South Africa.
A 16-year-old male with hypermobility spectrum disorder (HSD) and Raynaud's phenomenon (RP) was referred to a clinical exercise physiologist (CEP) by their pediatric rheumatologist. The patient presented with arthralgia in the left knee and shoulder. Specifically, the left knee presented discomfort during activities of daily living (ADL), and the left shoulder had a reduced range of motion resulting from pain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!